Real Time Genomics and Knome Ink Deal to Integrate and Sell the RTG Variant Platform on knoSYS100 System

Partnership to bring accurate and fast genome analysis to translational researchers.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend

SAN FRANCISCO, CA (PRWEB) May 06, 2013

Real Time Genomics, Inc., the genome analytics company, and Knome, Inc., the human genome interpretation company, today announced that the Real Time Genomics (RTG) Variant platform will be integrated into every shipment of the knoSYS™100 interpretation system. The agreement enables customers to easily purchase the RTG analytics engine as an upgrade to the system. The product will combine two world-class commercial platforms to deliver end-to-end genome analytics and interpretation with superior accuracy and speed. Financial terms of the agreement were not disclosed.

“In the past year demand for genome interpretation has surged as translational researchers and clinicians adopt sequencing for human disease discovery and diagnosis,” said Wolfgang Daum, CEO of Knome. “Concomitant with that demand is the need for accurate and easy-to-use industrial grade analysis that meets expectations of clinical accuracy. The RTG platform is both incredibly fast and truly differentiating to customers doing family studies, and we are excited to add such a powerful platform to the knoSYS ecosystem.”

The partnership simplifies the purchasing process by allowing knoSYS customers to purchase the RTG platform directly from Knome sales representatives.

“The Knome system is a perfect complementary channel to further expand our commercial effort to bring the RTG platform to market,” said Steve Lombardi, CEO of Real Time Genomics. “Knome has built a recognizable brand around human clinical genome interpretation, and by delivering the RTG platform within their system, both company’s are simplifying genomics to help customers understand human disease and guide clinical actions.”

About Real Time Genomics

Real Time Genomics (http://www.realtimegenomics.com) has a passion for genomics. The company offers software tools and applications for the extraction of unique value from genomes. Its competency lies in applying the combination of its patented core technology and deep computational expertise in algorithms to solve problems in next generation genomic analysis. Real Time Genomics is a private San Francisco based company backed by investment from Catamount Ventures, Lightspeed Venture Partners, and GeneValue Ltd.

About Knome

Knome Inc. is a leading provider of human genome interpretation systems and services. Knome provides tools and solutions that help researchers, drug developers, and clinicians determine the genetic basis of human disease and drug response. Designed to accelerate and industrialize the process of interpreting whole genomes, Knome’s big data technologies are helping to pave the healthcare industry’s transition to molecular-based, precision medicine.

Press contact for Real Time Genomics:
Jason Blue-Smith
jason(at)realtimegenomics(dot)com
(415) 420-4574

Press contact for Knome:
Jonas Lee
jlee(at)knome(dot)com
(617) 715-1000 x7001


Contact

  • Steve Lombardi

    925.487.7110
    Email